Age-dependent efficacy of Bifidobacterium strains on cognitive impairment and dementia: A systematic review and meta-analysis

IF 12.4 1区医学 Q1 CELL BIOLOGY

Ageing Research Reviews Pub Date : 2025-07-31 DOI:10.1016/j.arr.2025.102850

Wenliang Yu , Yao Li , Zeyang Liu , Siqi Hua , Ziyi Tan , Wei Tang , Mengyue Gao , Xiaoran Zhou , Zichun Hua

{"title":"Age-dependent efficacy of Bifidobacterium strains on cognitive impairment and dementia: A systematic review and meta-analysis","authors":"Wenliang Yu , Yao Li , Zeyang Liu , Siqi Hua , Ziyi Tan , Wei Tang , Mengyue Gao , Xiaoran Zhou , Zichun Hua","doi":"10.1016/j.arr.2025.102850","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Cognitive impairment and dementia are prevalent and costly diseases, affecting 5–8 % of individuals aged 60 and above globally. <em>Bifidobacterium</em>, a low-cost probiotic, has shown potential in treating dementia, but its efficacy remains controversial. To investigate the effects of <em>Bifidobacterium</em> on various dementia-related functional tests and biomarkers in different patient populations with cognitive impairment and dementia.</div></div><div><h3>Methods</h3><div>Systematic searches were conducted on February 15, 2025, across Embase, PubMed, Medline, Wanfang, and ClinicalTrials.gov. The risk of bias was assessed using NOS. The study is registered with PROSPERO (CRD42023460809).</div></div><div><h3>Results</h3><div>After rigorous screening, 18 studies encompassing 1195 patients were included. The results revealed that <em>Bifidobacterium</em> significantly improved cognitive function (MMSE, WMD = 2.26, 95 % CI = 1.69–2.83, compared to placebo: p = 0.049), particularly in patients under 70 (MMSE, WMD = 2.81, 95 % CI = 1.97–3.65). For patients over 70, better outcomes were achieved without <em>B. breve</em>-based treatments (MMSE, WMD = 2.43, 95 % CI = 1.76–3.09, compared to the group age under 70 or the group over 70 and receiving <em>B. breve</em>-based treatments: p = 0.0133). Additionally, <em>Bifidobacterium</em> significantly enhance patients’ memory, language, visuospatial, attention and executive abilities, potentially through the downregulation of triglycerides (WMD = −19.52, 95 % CI = −32.28 to −6.66, p = 0.039) and MDA (SMD = −0.72, 95 % CI = −1.07 to −0.37, p = 0.0057).</div></div><div><h3>Conclusions</h3><div>These findings provide key insights into the efficacy of <em>Bifidobacterium</em>, supporting personalized treatment strategies and reducing the treatment burden for patients with cognitive impairment and dementia.</div></div>","PeriodicalId":55545,"journal":{"name":"Ageing Research Reviews","volume":"111 ","pages":"Article 102850"},"PeriodicalIF":12.4000,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ageing Research Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1568163725001965","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

Cognitive impairment and dementia are prevalent and costly diseases, affecting 5–8 % of individuals aged 60 and above globally. Bifidobacterium, a low-cost probiotic, has shown potential in treating dementia, but its efficacy remains controversial. To investigate the effects of Bifidobacterium on various dementia-related functional tests and biomarkers in different patient populations with cognitive impairment and dementia.

Methods

Systematic searches were conducted on February 15, 2025, across Embase, PubMed, Medline, Wanfang, and ClinicalTrials.gov. The risk of bias was assessed using NOS. The study is registered with PROSPERO (CRD42023460809).

Results

After rigorous screening, 18 studies encompassing 1195 patients were included. The results revealed that Bifidobacterium significantly improved cognitive function (MMSE, WMD = 2.26, 95 % CI = 1.69–2.83, compared to placebo: p = 0.049), particularly in patients under 70 (MMSE, WMD = 2.81, 95 % CI = 1.97–3.65). For patients over 70, better outcomes were achieved without B. breve-based treatments (MMSE, WMD = 2.43, 95 % CI = 1.76–3.09, compared to the group age under 70 or the group over 70 and receiving B. breve-based treatments: p = 0.0133). Additionally, Bifidobacterium significantly enhance patients’ memory, language, visuospatial, attention and executive abilities, potentially through the downregulation of triglycerides (WMD = −19.52, 95 % CI = −32.28 to −6.66, p = 0.039) and MDA (SMD = −0.72, 95 % CI = −1.07 to −0.37, p = 0.0057).

Conclusions

These findings provide key insights into the efficacy of Bifidobacterium, supporting personalized treatment strategies and reducing the treatment burden for patients with cognitive impairment and dementia.

查看原文本刊更多论文

双歧杆菌菌株对认知障碍和痴呆的年龄依赖性疗效：一项系统综述和荟萃分析

目的认知障碍和痴呆是一种普遍且代价高昂的疾病，影响着全球5 - 8% %的60岁及以上老年人。双歧杆菌是一种低成本的益生菌，已显示出治疗痴呆症的潜力，但其有效性仍存在争议。探讨双歧杆菌对不同认知障碍和痴呆患者群体中各种痴呆相关功能测试和生物标志物的影响。方法系统检索于2025年2月15日在Embase、PubMed、Medline、万方和ClinicalTrials.gov进行。使用NOS评估偏倚风险。该研究已在PROSPERO注册（CRD42023460809）。结果经过严格筛选，纳入了18项研究，共1195例患者。结果显示，与安慰剂相比，双歧杆菌显著改善认知功能（MMSE, WMD = 2.26, 95 % CI = 1.69-2.83, p = 0.049），特别是在70岁以下患者（MMSE, WMD = 2.81, 95 % CI = 1.97-3.65）。对于70岁以上的患者，与年龄在70岁以下的组或年龄在70岁以上接受短芽孢杆菌治疗的组相比，不接受短芽孢杆菌治疗的患者获得了更好的结果（MMSE, WMD = 2.43, 95 % CI = 1.76-3.09: p = 0.0133）。此外，双歧杆菌显著增强患者的记忆、语言、视觉空间、注意力和执行能力，可能是通过下调甘油三酯（WMD = - 19.52, 95 % CI = - 32.28至- 6.66,p = 0.039）和MDA （SMD = - 0.72, 95 % CI = - 1.07至- 0.37,p = 0.0057）。结论这些发现为双歧杆菌的疗效提供了关键见解，支持个性化治疗策略，减轻认知障碍和痴呆患者的治疗负担。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ageing Research Reviews 医学-老年医学

CiteScore

19.80

自引率

2.30%

发文量

216

审稿时长

55 days

期刊介绍： With the rise in average human life expectancy, the impact of ageing and age-related diseases on our society has become increasingly significant. Ageing research is now a focal point for numerous laboratories, encompassing leaders in genetics, molecular and cellular biology, biochemistry, and behavior. Ageing Research Reviews (ARR) serves as a cornerstone in this field, addressing emerging trends. ARR aims to fill a substantial gap by providing critical reviews and viewpoints on evolving discoveries concerning the mechanisms of ageing and age-related diseases. The rapid progress in understanding the mechanisms controlling cellular proliferation, differentiation, and survival is unveiling new insights into the regulation of ageing. From telomerase to stem cells, and from energy to oxyradical metabolism, we are witnessing an exciting era in the multidisciplinary field of ageing research. The journal explores the cellular and molecular foundations of interventions that extend lifespan, such as caloric restriction. It identifies the underpinnings of manipulations that extend lifespan, shedding light on novel approaches for preventing age-related diseases. ARR publishes articles on focused topics selected from the expansive field of ageing research, with a particular emphasis on the cellular and molecular mechanisms of the aging process. This includes age-related diseases like cancer, cardiovascular disease, diabetes, and neurodegenerative disorders. The journal also covers applications of basic ageing research to lifespan extension and disease prevention, offering a comprehensive platform for advancing our understanding of this critical field.